AZN — AstraZeneca PLC

Is AZN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Overbought As of November 17, 2026

AstraZeneca PLC (AZN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $182.27. The rating moved from Neutral to Overbought on October 30, 2026.

See all overbought Healthcare stocks →

AI analysis

AstraZeneca PLC (AZN) combines a diversified commercial portfolio, a deep R&D pipeline and recent dual approvals that bolster near‑term revenue visibility. Defensive flows into large-cap pharma and positive readthroughs from obesity/GLP‑1/amylin data support demand for the shares. The company’s strong cash generation and balance sheet underpin continued investment in late‑stage programs and selective M&A to expand specialty franchises. Key risks include payer/regulatory pressure, competitive dynamics in high-growth therapeutic areas, and clinical/regulatory setbacks that could derail expectations.

Key factors

  • Recent regulatory approvals across US and Europe for rare disease and bladder cancer expand near-term revenue visibility and reduce binary clinical risk for parts of the portfolio
  • Large-cap pharma defensive flows are supporting demand for diversified, cash-generative pharmaceutical names, benefiting AstraZeneca PLC (AZN)
  • Diversified product mix across oncology, rare disease, cardiovascular/renal/metabolism and respiratory provides multiple revenue streams and reduces single-product dependence
  • Strong R&D engine and late-stage pipeline with multiple assets in oncology and specialty care that can drive medium-term upside
  • Healthy balance sheet and cash generation support continued R&D investment and opportunistic M&A to fill specialty franchise gaps
  • Positive social sentiment from recent approvals and sector readthroughs for obesity/GLP-1/amylin data that favor large, diversified pharma

Risks

  • Regulatory and pricing pressure (including CMS proposals around Medicare Advantage and program integrity) that could pressure payer reimbursement dynamics and margins
  • Intense competition in key franchises (oncology, obesity/GLP‑1 readthroughs from competitors such as Novo Nordisk) that could limit peak sales or market share
  • Clinical or regulatory setbacks in late‑stage trials could materially affect forward guidance and valuation
  • Patent expirations or faster generic/biosimilar uptake on key products that reduce revenue visibility
  • Currency fluctuations and macroeconomic weakness in developed/emerging markets impacting reported results
  • M&A execution risk and integration challenges if management pursues larger strategic transactions

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AZN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.